PMID- 35798506
OWN - NLM
STAT- MEDLINE
DCOM- 20220711
LR  - 20220714
IS  - 1937-6448 (Print)
IS  - 1937-6448 (Linking)
VI  - 370
DP  - 2022
TI  - Dendritic cell transfer for cancer immunotherapy.
PG  - 33-64
LID - S1937-6448(22)00024-7 [pii]
LID - 10.1016/bs.ircmb.2022.03.003 [doi]
AB  - Dendritic cells (DCs) play a major role in cancer immunosurveillance as they 
      bridge innate and adaptive immunity by detecting tumor-associated antigens and 
      presenting them to T lymphocytes. The adoptive transfer of antigen loaded DCs has 
      been proposed as an immunotherapeutic approach for the treatment of various types 
      of cancer. Nevertheless, despite promising preclinical data, the therapeutic 
      efficacy of DC transfer is still deceptive in cancer patients. Here we summarize 
      recent findings in DC biology with a special focus on the development of 
      actionable therapeutic strategies and discuss experimental and clinical 
      approaches that aim at improving the efficacy of DC-based immunotherapies, 
      including, but not limited to, optimized DC production and antigen loading, 
      stimulated maturation, the co-treatment with additional immunotherapies, as well 
      as the inhibition of DC checkpoints.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Zhao, Liwei
AU  - Zhao L
AD  - Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Universite 
      Paris Saclay, Villejuif, France; Centre de Recherche des Cordeliers, Equipe 
      labellisee par la Ligue contre le cancer, Universite de Paris, Sorbonne 
      Universite, Inserm U1138, Institut Universitaire de France, Paris, France.
FAU - Zhang, Shuai
AU  - Zhang S
AD  - Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Universite 
      Paris Saclay, Villejuif, France; Centre de Recherche des Cordeliers, Equipe 
      labellisee par la Ligue contre le cancer, Universite de Paris, Sorbonne 
      Universite, Inserm U1138, Institut Universitaire de France, Paris, France.
FAU - Kepp, Oliver
AU  - Kepp O
AD  - Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Universite 
      Paris Saclay, Villejuif, France; Centre de Recherche des Cordeliers, Equipe 
      labellisee par la Ligue contre le cancer, Universite de Paris, Sorbonne 
      Universite, Inserm U1138, Institut Universitaire de France, Paris, France. 
      Electronic address: captain.olsen@gmail.com.
FAU - Kroemer, Guido
AU  - Kroemer G
AD  - Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Universite 
      Paris Saclay, Villejuif, France; Centre de Recherche des Cordeliers, Equipe 
      labellisee par la Ligue contre le cancer, Universite de Paris, Sorbonne 
      Universite, Inserm U1138, Institut Universitaire de France, Paris, France; 
      Institut du Cancer Paris Carpem, Department of Biology, Hopital Europeen Georges 
      Pompidou, APHP, Paris, France. Electronic address: kroemer@orange.fr.
FAU - Liu, Peng
AU  - Liu P
AD  - Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Universite 
      Paris Saclay, Villejuif, France; Centre de Recherche des Cordeliers, Equipe 
      labellisee par la Ligue contre le cancer, Universite de Paris, Sorbonne 
      Universite, Inserm U1138, Institut Universitaire de France, Paris, France. 
      Electronic address: kunzhiling@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220629
PL  - Netherlands
TA  - Int Rev Cell Mol Biol
JT  - International review of cell and molecular biology
JID - 101475846
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Antigens, Neoplasm/metabolism
MH  - *Cancer Vaccines
MH  - Dendritic Cells
MH  - Humans
MH  - Immunotherapy
MH  - *Neoplasms/metabolism
MH  - T-Lymphocytes
OTO - NOTNLM
OT  - CRISPR
OT  - Checkpoint blockade
OT  - Gene editing
OT  - Immunogenic cell death
OT  - iniDC
COIS- Conflict of interest GK and OK are cofounders of Samsara Therapeutics. GK is a 
      cofounder of everImmune and Therafast Bio.
EDAT- 2022/07/08 06:00
MHDA- 2022/07/12 06:00
CRDT- 2022/07/07 21:04
PHST- 2022/07/07 21:04 [entrez]
PHST- 2022/07/08 06:00 [pubmed]
PHST- 2022/07/12 06:00 [medline]
AID - S1937-6448(22)00024-7 [pii]
AID - 10.1016/bs.ircmb.2022.03.003 [doi]
PST - ppublish
SO  - Int Rev Cell Mol Biol. 2022;370:33-64. doi: 10.1016/bs.ircmb.2022.03.003. Epub 
      2022 Jun 29.